RETA Reata Pharmaceuticals Inc Class A

Reata Pharmaceuticals Inc is a clinical stage biopharmaceutical company engaged in identifying, developing, and commercializing product candidates to address rare and life-threatening diseases by targeting molecular pathways. The company has class B common shares outstanding that are privately held.

$30.45  +0.06 (0.20%)
As of 07/01/2022 15:59:56 EST     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  05/26/2016
Outstanding shares:  31,543,735
Average volume:  434,535
Market cap:   $958,614,107
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BYY9FX8

---

Valuation   (See tab for details)

---

PE ratio:   -3.16
PB ratio:   8.68
PS ratio:   83.66
Return on equity:   -237.72%
Net income %:   -2,650.96%